Celltrion Remsima SC anticipated to dominate and monopolize the Brazilian market… Suggestion for registration of SC formulation merchandise by federal authorities

by times news cr

2024-05-17 15:37:26

Countdown to product itemizing of infliximab SC formulation in Brazilian authorities system
Risk to dominate the market with the world’s solely infliximab SC formulation
Anticipated monopolization of the most important market in Latin America with a inhabitants of 210 million
“It should have a optimistic affect on the introduction of Remsima SC in neighboring nations.”

‘Remsima SC’, the world’s solely infliximab subcutaneous injection (SC) formulation remedy offered by Celltrion, is predicted to see fast development in Brazil, the most important market in Latin America. As there’s a excessive chance of it being listed as an merchandise within the native public medical system, it’s anticipated to monopolize the associated market with the infliximab SC formulation, which has no different.

Celltrion introduced on the seventeenth that the Technical Committee (CONITEC) below the Brazilian Ministry of Well being just lately really useful approval of the registration of infliximab SC formulation as a brand new product within the federal authorities’s public healthcare system. It’s anticipated that the merchandise itemizing shall be finalized within the second half of this yr after going by way of administrative procedures.

Via this new merchandise itemizing, a brand new public marketplace for the infliximab SC formulation, which didn’t exist earlier than, is predicted to be shaped in Brazil. Celltrion Remsima SC is the one product eligible. It’s anticipated that the corporate will be capable to shortly dominate the market and revel in a monopoly impact. Evaluation means that this determination was made by the Brazilian authorities to enhance the standard of well being care and strengthen affected person entry to remedy.

Brazil is a rustic with a inhabitants of 210 million folks and has greater than half of the pharmaceutical market in Latin America. Entry into the Brazilian market additionally impacts entry into different nations in Central and South America. Celltrion has established itself as a number one firm within the Brazilian biosimilar market and expects its affect available in the market to be additional solidified with the advice for itemizing this new merchandise.

Remsima, the intravenous injection (Ⅳ) formulation that was launched first, is alleged to have coated greater than 80% of the market with greater than 570,000 vials equipped in Brazil final yr, together with profitable orders from the federal authorities. As well as, following the itemizing of a brand new infliximab SC formulation within the federal authorities, an unique order for Remsima SC, the one merchandise eligible for bidding, is predicted. Celltrion believes that the enlargement of prescriptions for each merchandise will speed up as a result of added gross sales synergy of the Remsima product line.

Celltrion Remsima SC

Celltrion Remsima SC

Strengthening the market dominance of the Remsima lineup in Brazil is predicted to have a optimistic affect on gross sales of Celltrion’s different merchandise. As for different merchandise, greater than 73,000 vials and 66,000 vials of Herzuma (ingredient title: trastuzumab) and Truxima (rituximab) have been equipped as of final yr, respectively. Having occupied greater than half of the market, the corporate plans to pursue extra aggressive advertising and marketing actions to maximise efficiency.

Kang Kyeong-doo, head of Celltrion’s Central and South American area, mentioned, “Occupying the Brazilian market is essential as a result of it serves as a bridgehead to guide the enlargement of Remsima SC into neighboring Central and South American nations.” He added, “Because the second half of final yr, the native company has been offering Infliximab SC to authorities businesses. “Because of energetic communication, together with publicizing the necessity to kind a formulation market and submitting associated paperwork, we have been capable of obtain the results of creating situations for Remsima SC to be prescribed within the Brazilian public market.”

Celltrion predicts that this itemizing by the Brazilian federal authorities could have a optimistic affect on forming public opinion on the necessity to introduce the product, as nations close to Brazil, equivalent to Mexico, Chile, and Peru, are additionally contemplating itemizing it as a authorities buy merchandise.

Kim Min-beom, Donga.com reporter [email protected]

Scorching information now

2024-05-17 15:37:26

You may also like

Leave a Comment